SignalXSignalX

KRRO Korro Bio, Inc.

8-K Current Report
Filed: March 9, 2026
Health Care
Pharmaceutical Preparations
Korro Bio, Inc. Overview

Korro Bio, Inc. (KRRO) 8-K current report filed with SEC EDGAR on March 9, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
4 items

  • Item 1.01: Entry into a Material Definitive Agreement
  • Item 2.02: Results of Operations and Financial Condition
  • Item 3.02: Unregistered Sales of Equity Securities
  • Item 7.01: Regulation FD Disclosure

AI Filing Analysis
8-K

Item 1.01 · Entry into a Material Definitive Agreement

  • • Private placement raising ~$85.0M gross proceeds via 4.5M shares at $11.11/share plus pre-funded warrants for 3.1M additional shares at $11.109 each
  • • Combined with existing $85.2M cash (as of Dec 31, 2025), total runway extended into 2H 2028 — meaningful for a clinical-stage biotech burning cash on pipeline development
+3 more insights

Item 2.02 · Results of Operations and Financial Condition

  • • Cash, cash equivalents & marketable securities ~$85.2M as of Dec 31, 2025 (preliminary, unaudited)
  • • Figure subject to change pending completion of financial closing procedures — not yet audited or reviewed by external auditors
+1 more insights

Item 3.02 · Unregistered Sales of Equity Securities

  • • Item 3.02 covers unregistered securities sales; KRRO's disclosure cross-references another section of this 8-K rather than detailing terms here
  • • Investors should review the full 8-K for deal terms, share counts, and applicable exemptions from registration

Item 7.01 · Regulation FD Disclosure

  • • Private placement closing disclosed — terms and size not specified in this section; check accompanying exhibits for deal economics
  • • Preliminary unaudited year-end cash, cash equivalents, and marketable securities referenced — actual figures not disclosed in this item
+1 more insights

Other Korro Bio, Inc. 8-K Filings

8-K Mar 12, 2026

Get deeper insights on Korro Bio, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.